Baxitozine is a Histamine H2 receptor antagonist. It has a cytoprotective, antisecretory and antiulcer properties. In situ, baxitozine inhibited acid secretion stimulated by histamine or pentagastrin but was inactive against carbachol. It also had antiulcer activity against stress ulcers (restraint plus cold). It had marked gastric cytoprotective activity in rats against the necrotizing effects of ethanol. This cytoprotective activity was not significantly affected by indomethacin pre-treatment. Baxitozine has been in phase II clinical trials for the treatment of gastric ulcer. However, this research has been discontinued.